Immuno-pharma company AIM ImmunoTech has secured a patent from the Netherlands Patent Office for its RNA product candidate, Ampligen (rintatolimod), targeting the treatment of post-Covid-19 fatigue.

The patent, numbered 2,032,813, covers compositions and methods for using Ampligen to address this condition. The patent's two inventors, CEO Thomas Equels and medical officer David Strayer, have assigned it to the company.

Ampligen can modulate the immune system and has demonstrated broad-spectrum antiviral effects in studies. Experiments also showed that the therapy significantly impacted viral replication, particularly in SARS-CoV-2.

The company has completed a Phase II study, known as AMP-518, to assess the therapy's safety and efficacy in treating the given condition. The study's topline outcomes indicated that it was well-tolerated and provided preliminary evidence of its potential to decrease fatigue in individuals with post-Covid conditions.

Based on complete clinical subject data from the AMP-518 trial, the company believes the therapy could be an option for those suffering from moderate-to-severe post-Covid fatigue. Targeting this patient population, the company is planning a follow-up clinical trial.

AIM ImmunoTech CEO Thomas Equels stated: "Over the course of the past year in particular, we have had great success in expanding our global intellectual property portfolio, with US patents for the combination of Ampligen with immune checkpoint inhibitors for the treatment of challenging cancers, for a novel method for the treatment of chronic fatigue syndrome, and for methods and compositions for treating debilitating endometriosis.

"We are pleased to continue executing on that initiative and to further broaden AIM's existing portfolio for the treatment of Covid-19-related illnesses with this new Netherlands patent. Much of our European research is conducted in the Netherlands at the world-renowned Erasmus Medical Center."

AIM ImmunoTech focuses on developing therapies for diseases including multiple types of immune disorders, cancers and viral conditions.

"AIM ImmunoTech gains Netherlands patent for post-Covid fatigue therapy" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.